Helper-Dependent Adenoviral Vectors for Gene Therapy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Helper-dependent adenoviral vectors possess a number of characteristics that make them attractive gene therapy vectors. These vectors are completely devoid of viral coding sequences and are able to mediate high-efficiency transduction in vivo to direct sustain high-level transgene expression with negligible chronic toxicity. This review focuses on advances in helper-dependent adenoviral vector technology, selected examples of in vivo studies of particular interest, and the issue of vector-mediated acute toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725 · cited 4×
“Since the development of the original Cre– loxP system (Parks et al ., 1996), a number of similar systems have been re-ported that use the same basic strategy of selective excision, by site-specific recombination, of the helper virus (cid:1) for preferential HDAd propagation (Hardy et al ., 1997;…”
InfluentialPackaging capacity and stability of human adenovirus type 5 vectors
Bett, A. J., Prevec, L., & Graham, F. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.5911-5921.1993 · Cited by 472
Cited by
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1450 · Cited by 469
Muruve, D. A., Barnes, M. J., Stillman, I. E., & Libermann, T. A. (1999) · Human Gene Therapy · doi:10.1089/10430349950018364 · Cited by 447
Raper, S. E., Yudkoff, M., Chirmule, N., Gao, G.-P., Nunes, F., Haskal, Z. J., Furth, E. E., Propert, K. J., Robinson, M. B., Magosin, S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712719 · Cited by 354
Gutless adenovirus: last-generation adenovirus for gene therapy
Alba, R., Bosch, A., & Chillon, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302612 · Cited by 303
Improved system for helper-dependent adenoviral vector production
Palmer, D., & Ng, P. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.08.014 · Cited by 290
Self-citationBrunetti-Pierri, N., Palmer, D. J., Beaudet, A. L., Carey, K. D., Finegold, M., & Ng, P. (2004) · Human Gene Therapy · doi:10.1089/10430340460732445 · Cited by 256
Self-citationCurrent Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Campos, S., & Barry, M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859062 · Cited by 210
“The elimination of Ad antigen expression in HD-Ad vectors permits long-term episomal expression of genes in quiescent cells by avoiding problems associated with the cellular immune response against viral gene products [Palmer & Ng, 2005, Toietta et al., 2005].”
Proteoglycan 4 Expression Protects Against the Development of Osteoarthritis
Ruan, M. Z. C., Erez, A., Guse, K., Dawson, B., Bertin, T., Chen, Y., Jiang, M.-M., Yustein, J., Gannon, F., & Lee, B. H. L. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005409 · Cited by 196
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Advances in Gene Delivery Systems
Kamimura, K., Suda, T., Zhang, G., & Liu, D. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256872 · Cited by 124
Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors
Gregory, S. M., Nazir, S. A., & Metcalf, J. P. (2011) · Future Virology · doi:10.2217/fvl.11.6 · Cited by 89
“Additional sophisticated techniques, such as adding ‘stuffer DNA’ to prevent the formation of undesired contaminating vectors by exploiting packaging limitations of AdV, have been developed [206,211].”
MethodLamartina, S., Cimino, M., Roscilli, G., Dammassa, E., Lazzaro, D., Rota, R., Ciliberto, G., & Toniatti, C. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1083 · Cited by 59
“Moreover, HDAd vectors can accommodate up to 35 kb of exogenous DNA, thus enabling the delivery of long transgenes, large regulatory regions and multiple expression cassettes [24].”
BackgroundGenetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Metadata
- Authors
- Palmer, D. J., & NG, P.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2005-01
- Volume
- 16
- Issue
- 1
- Pages
- 1-16
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2007276010
- Cited by
- 194
- References
- 2
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.